Die Seestadt Apotheke in 1220, Wien, lädt zu ihrem kosmetischen Beratungstag am 29.11.2022 ein. Unterstützt durch Produkte von Eucerin, wird Scarletred exklusiv helfen den Hautzustand zu erfassen und analysieren.

The 6th Dermatology Drug Development Summit for inflammatory skin diseases gives insight into novel therapeutics and patient-specific and alternative treatment options currently in clinical trials for various skin diseases.

Following a successful launch in Europe in 2019, and a tremendous online experience in 2021, the 3rd Dermatology Drug Development Europe Summit, returns in April 2022 in Frankfurt, Germany.

In an interview, specialist Dr. Zikeli discusses the clinical characteristics of atopic dermatitis and why documentation using Scarletred®Vision is an optimal support for diagnosis and progress monitoring.

The 5th Annual Dermatology Drug Development Summit focusing on development and innovation of therapies and research targeting inflammatory skin diseases, returns to Boston for 2021.

The Inflammatory Skin Disease Summit is a jointly organized event by the Icahn School of Medicine at Mount Sinai and the Austrian Academy of Sciences.

The clinically validated and award-winning technology, Scarletred®Vision, is on market since 2015, enabling high quality remote skin imaging and objective analysis in over 3000 cutaneous disorders.

​​In the round table discussion of the leading financial domain Börse Express, Marinomed, Scarletred, PHH Rechtsanwälte, and EOSS Industries discussed the development and hurdles of Austrian life science start-ups.

Hidradenitis suppurativa (HS) is an autoinflammatory skin condition that causes abscesses and scarring on the skin and affects about 1-4% of the total population (Ballard & Schuman, 2020). 

People suffering from atopic dermatitis struggle with the condition itself and stigmatization, making digital analysis of disease and treatment vital to clinical management to enhance their quality of life using SCARLETRED.

SCARLETRED’s certified medical device provides medical professionals with a novel digital solution to allow them to assess and analyze the individuals’ affected areas in an accurate, time-efficient, and user-friendly manner.

The traditional assessment of skin texture based on multiple health professionals can lead to inconsistent results making standardized digital dermatological monitoring, as provided by SCARLETRED, an essential tool.

Psoriasis is a chronic inflammatory disease of the skin associated with red, raised plaques and scaly skin. Psoriasis is a global problem affecting approximately 2-3% of the total population.

Patient-reported outcome (PRO) refers to a health outcome directly based on patient self-reporting. While some measures can be captured during site visits, others may be tracked more efficiently close to real-time.

SCARLETRED’s mobile technology, Scarletred®Vision, provides clinically validated R&D tools to document, analyse, and monitor skin color and pigmentation variations in multi-centric or home based cosmetics studies.

Onychomycosis is an infection of the nail caused by fungal organisms. With SCARLETRED’s digital technology, experts can quantify and monitor disease progression allowing for consistent and personalized treatment.

Being a chronic inflammatory skin disorder, patients with rosacea need standardized tools, as provided by SCARLETRED, to improve the condition’s analysis and treatment and overcome psychosocial stigmatization.

Standardized documentation and scoring of injection site reactions is a crucial part of clinical trials, as local development of skin erythema can reflect on the effectiveness and side effects of an investigational product.

Skin cancer is one of the most common types of cancer but also the most preventable one. The incidence rates for non-melanoma skin cancer drastically increased, and currently, there are 2-3 million cases each year.

Solar lentigo, also called age spots, is a common form of hyperpigmentation, especially in adults older than 50, caused by natural or artificial ultraviolet light exposure.

Vitiligo is a long-term pigmentation disorder affecting 0.5 - 1% of individual. SCARLETRED is revolutionizing dermatology by allowing the standardization of the assessment and monitoring of vitiligo.

The skin is the primary interface between nurse and patient. With SCARLETRED, pigmentation disorders can be objectively monitored, improving dermatological and cosmetic dermatological services.

Non-healing wounds pose a significant challenge in clinical medicine and present severe difficulties to millions of patients worldwide. The management of chronic wounds remains a challenging task in terms of their assessment.

Due to the COVID-19 pandemic, researchers need to adjust clinical trial setups due to the stay-at-home orders and risk of virus transmission. The golden time of virtual and home-based clinical trials has started.

The current COVID-19 pandemics forced many clinical trials to grind to a halt, stalling research until restrictions are lifted. Scarletred offers a solution for the documentation and monitoring of changes on the skin surface.